PMID- 35118452
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20220205
IS  - 2752-5457 (Electronic)
IS  - 2752-5457 (Linking)
VI  - 17
IP  - 2
DP  - 2021 Nov
TI  - Finerenone: A Potential Treatment for Patients with Chronic Kidney Disease and 
      Type 2 Diabetes Mellitus.
PG  - 84-87
LID - 10.17925/EE.2021.17.2.84 [doi]
AB  - Type 2 diabetes mellitus (T2DM) affects an estimated 463 million people 
      worldwide, equivalent to 1 in 11 adults. Moreover, the rapid growth of this 
      disease has resulted in a high incidence of diabetic kidney disease (DKD), which, 
      together with hypertension, is the main cause of chronic kidney disease (CKD). 
      Hyperglycaemia, low-grade inflammation, altered lipid metabolism and 
      hyperactivation of the renin-angiotensin-aldosterone system (RAAS) seem to be 
      interrelated mechanisms contributing to both T2DM and microvascular 
      complications. The introduction of drugs such as sodium-glucose cotransporter 2 
      inhibitors and glucagon-like peptide 1 receptor agonists has improved the ability 
      to slow the progression of DKD, and has also demonstrated benefits in 
      cardiovascular disease. Beyond the effects of these novel antidiabetic drugs, a 
      body of evidence suggests that the overactivation of the mineralocorticoid 
      receptor also contributes to CKD progression. Moreover, new and ongoing trials 
      have demonstrated that the selective nonsteroidal mineralocorticoid receptor 
      antagonist (MRA) finerenone improves the risk of CKD progression and 
      cardiovascular events in patients with CKD and T2DM and optimized RAAS blockade. 
      We review the rationale for the development and use of MRA drugs to slow CKD 
      progression in patients with DKD, as well as other pleiotropic effects, and 
      highlight the warnings associated with these agents.
CI  - (c) Touch Medical Media 2021.
FAU - D'Marco, Luis
AU  - D'Marco L
AD  - Nephrology Department, Hospital Clinico Universitario, Instituto de Investigacion 
      Sanitaria (INCLIVA), Valencia, Spain.
AD  - Centro de Estudios Universitarios Cardenal Herrera University, Valencia, Spain.
FAU - Puchades, Maria Jesus
AU  - Puchades MJ
AD  - Nephrology Department, Hospital Clinico Universitario, Instituto de Investigacion 
      Sanitaria (INCLIVA), Valencia, Spain.
AD  - Valencia University, Valencia, Spain.
FAU - Gandia, Lorena
AU  - Gandia L
AD  - Nephrology Department, Hospital Clinico Universitario, Instituto de Investigacion 
      Sanitaria (INCLIVA), Valencia, Spain.
FAU - Forquet, Claudia
AU  - Forquet C
AD  - Nephrology Department, Hospital Clinico Universitario, Instituto de Investigacion 
      Sanitaria (INCLIVA), Valencia, Spain.
FAU - Gimenez-Civera, Elena
AU  - Gimenez-Civera E
AD  - Nephrology Department, Hospital Clinico Universitario, Instituto de Investigacion 
      Sanitaria (INCLIVA), Valencia, Spain.
FAU - Panizo, Nayara
AU  - Panizo N
AD  - Nephrology Department, Hospital Clinico Universitario, Instituto de Investigacion 
      Sanitaria (INCLIVA), Valencia, Spain.
FAU - Reque, Javier
AU  - Reque J
AD  - Nephrology Department, Hospital de Castellon, Castellon, Spain.
FAU - Juan-Garcia, Isabel
AU  - Juan-Garcia I
AD  - Nephrology Department, Hospital Clinico Universitario, Instituto de Investigacion 
      Sanitaria (INCLIVA), Valencia, Spain.
FAU - Bermudez, Valmore
AU  - Bermudez V
AD  - Facultad de Ciencias de la Salud, Universidad Simon Bolivar, Barranquilla, 
      Colombia.
FAU - Gorriz, Jose Luis
AU  - Gorriz JL
AD  - Nephrology Department, Hospital Clinico Universitario, Instituto de Investigacion 
      Sanitaria (INCLIVA), Valencia, Spain.
AD  - Valencia University, Valencia, Spain.
LA  - eng
PT  - Journal Article
PT  - Review
DEP - 20211110
PL  - England
TA  - touchREV Endocrinol
JT  - TouchREVIEWS in endocrinology
JID - 101779126
PMC - PMC8676102
OTO - NOTNLM
OT  - Chronic kidney disease
OT  - cardiovascular diseases
OT  - diabetic nephropathies
OT  - finerenone
COIS- Disclosures: Jose Luis Gorriz has received speakers' fees and funding for 
      attending advisory boards from Bayer. Luis D'Marco, Maria Jesus Puchades, Lorena 
      Gandia, Claudia Forquet, Elena Gimenez-Civera, Nayara Panizo, Javier Reque, 
      Isabel Juan-Garcia and Valmore Bermudez have no financial or nonfinancial 
      relationships or activities to declare in relation to this article.
EDAT- 2022/02/05 06:00
MHDA- 2022/02/05 06:01
PMCR- 2021/11/01
CRDT- 2022/02/04 05:54
PHST- 2021/06/29 00:00 [received]
PHST- 2021/09/28 00:00 [accepted]
PHST- 2022/02/04 05:54 [entrez]
PHST- 2022/02/05 06:00 [pubmed]
PHST- 2022/02/05 06:01 [medline]
PHST- 2021/11/01 00:00 [pmc-release]
AID - 10.17925/EE.2021.17.2.84 [doi]
PST - ppublish
SO  - touchREV Endocrinol. 2021 Nov;17(2):84-87. doi: 10.17925/EE.2021.17.2.84. Epub 
      2021 Nov 10.